INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 416m ago
HOUSE PTR15m ago
SEC 13F15m ago
ROBINHOOD CHAIN15m ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Venker Eric reported ROIV

President & Immunovant CEO · Roivant Sciences Ltd. · Roivant Sciences Ltd. — Stock Option (Right to Buy)

Side
M
Value
—
Shares
200.0K
Price
—
Executed
Apr 20, 2026
Disclosed
Apr 22, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Apr 20 executedApr 22, 2026 disclosed

ROIV · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · 4.5% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ROIV

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    11
    VE
    Venker EricPresident & Immunovant CEO
    ROIVRoivant Sciences Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$7.26M
    200.0K sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    14
    VE
    Venker EricPresident & Immunovant CEO
    ROIVRoivant Sciences Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$7.32M
    200.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    EB
    Epperly Melissa B,Director
    ROIVRoivant Sciences Ltd.
    Tax withholding
    		F$4,233
    116 sh
    		Oct 23, 2026Oct 27, 2026
    traded Oct 23, 2026
    		+4dSEC FORM 4

    Evidence

    9
    OI
    Oren IlanDirector
    ROIVRoivant Sciences Ltd.
    Grant or award
    		A—
    810 sh
    		Oct 23, 2026Oct 27, 2026
    traded Oct 23, 2026
    		+4dSEC FORM 4

    Evidence

    9
    EB
    Epperly Melissa B,Director
    ROIVRoivant Sciences Ltd.
    Grant or award
    		A—
    513 sh
    		Oct 23, 2026Oct 27, 2026
    traded Oct 23, 2026
    		+4dSEC FORM 4

    Evidence

    7
    VE
    Venker EricPresident & Immunovant CEO
    ROIVRoivant Sciences Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$501K
    14.1K sh
    		Oct 20, 2026Oct 22, 2026
    traded Oct 20, 2026
    		+2dSEC FORM 4

    Evidence

    14
    VE
    Venker EricPresident & Immunovant CEO
    ROIVRoivant Sciences Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$6.52M
    185.9K sh
    		Oct 20, 2026Oct 22, 2026
    traded Oct 20, 2026
    		+2dSEC FORM 4

    Evidence

    15
    SM
    Sukhatme MayukhDirector, President & CIO
    ROIVRoivant Sciences Ltd.
    Tax withholding
    		F$670K
    20.0K sh
    		Oct 16, 2026Oct 20, 2026
    traded Oct 16, 2026
    		+4dSEC FORM 4

    Evidence

    14
    GM
    Gline MatthewDirector, CEO
    ROIVRoivant Sciences Ltd.
    Tax withholding
    		F$1.16M
    34.6K sh
    		Oct 16, 2026Oct 20, 2026
    traded Oct 16, 2026
    		+4dSEC FORM 4

    Evidence

    12
    PR
    Pulik RichardCFO
    ROIVRoivant Sciences Ltd.
    Tax withholding
    		F$85K
    2,129 sh
    		Sep 20, 2026Sep 22, 2026
    traded Sep 20, 2026
    		+2dSEC FORM 4

    Evidence

    9
    EB
    Epperly Melissa B,Director
    ROIVRoivant Sciences Ltd.
    Grant or award
    		A—
    10.5K sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GA
    Gold Daniel AllenDirector
    ROIVRoivant Sciences Ltd.
    Grant or award
    		A—
    5,054 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    9
    OI
    Oren IlanDirector
    ROIVRoivant Sciences Ltd.
    Grant or award
    		A—
    5,054 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    9
    OI
    Oren IlanDirector
    ROIVRoivant Sciences Ltd.
    Grant or award
    		A—
    10.5K sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GA
    Gold Daniel AllenDirector
    ROIVRoivant Sciences Ltd.
    Grant or award
    		A—
    10.5K sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    21
    EB
    Epperly Melissa B,Director
    ROIVRoivant Sciences Ltd.
    Grant or award
    		A—
    5,054 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    16
    EB
    Epperly Melissa B,Director
    ROIVRoivant Sciences Ltd.
    Tax withholding
    		F$89K
    2,179 sh
    		Sep 10, 2026Sep 14, 2026
    traded Sep 10, 2026
    		+4dSEC FORM 4

    Evidence

    0
    VE
    Venker EricPresident & Immunovant CEO
    ROIVRoivant Sciences Ltd.
    Option exercise · 10b5-1 plan
    		M—
    200.0K sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    14
    VE
    Venker EricPresident & Immunovant CEO
    ROIVRoivant Sciences Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$5.08M
    153.8K sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    5
    VE
    Venker EricPresident & Immunovant CEO
    ROIVRoivant Sciences Ltd.
    Option exercise · 10b5-1 plan
    		M$770K
    200.0K sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001635088-26-000044
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Apr 20, 2026
    Published
    Apr 22, 2026
    Ingested by INSIDER
    Nov 5, 04:03 UTC
    Last re-read
    Nov 5, 04:03 UTC

    Extracted facts

    Filer
    Venker Eric
    Role
    President & Immunovant CEO
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Roivant Sciences Ltd. — Stock Option (Right to Buy)
    Ticker
    ROIV
    Shares
    200.0K
    Price per share
    $0
    Execution date (reported)
    Apr 20, 2026
    Owned after transaction
    4.64M shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    What this establishes

    Venker Eric filed this Form 4 reporting a option exercise of ROIV on Apr 20, 2026. It became public on Apr 22, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    President & Immunovant CEO
    Venker Ericcik:0001801917
    Issuer
    Roivant Sciences Ltd.cik:0001635088

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.